Crinetics Pharmaceuticals to Announce Q2 2024 Financial Results on August 8, 2024

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the market closes. The company’s management will hold a conference call at 4:30 p.m. ET on that day to discuss these financial results and provide a business update. 

To participate in the conference call, individuals can dial 1-800-267-6316 within the United States or 1-203-518-9783 for international calls, using the conference ID CRNXQ2. Participants also have the option to join the call via a live webcast available in the Events section of Crinetics' website. It is advised that participants connect or register at least 15 minutes before the call starts to ensure a smooth connection. Following the call, the webcast will be archived on the Investor Relations section of the Crinetics website.

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to creating and developing novel treatments for endocrine diseases and related tumors. Among its leading drug candidates is Paltusotine, an investigational oral somatostatin receptor type 2 (SST2) agonist, which is currently in Phase 3 clinical trials for the treatment of acromegaly and in Phase 2 trials for addressing carcinoid syndrome associated with neuroendocrine tumors.

Another prominent drug candidate from Crinetics is Atumelnant (CRN04894), an investigational oral ACTH antagonist. This drug is completing Phase 2 clinical trials for treating congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. 

All the drugs under development at Crinetics are new chemical entities that are orally administered. These drugs are the result of the company's in-house drug discovery efforts. The company also has ongoing discovery programs targeting a range of endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes, and obesity.

Crinetics Pharmaceuticals is committed to advancing its pipeline of innovative therapies to address unmet medical needs within the endocrine disease space. The company continues to leverage its expertise in endocrine biology and drug discovery to develop treatments that improve the lives of patients with significant health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!